Pfizer ordered to pay $142M for Neurontin marketing fraud 
By:
Nora Tooher
Published: March 26, 2010
Tags: Kaiser, Neurontin, off-label uses, Pfizer
BOSTON – A federal jury Thursday found that Pfizer violated anti-racketeering laws in promoting its epilepsy drug Neurontin for unapproved uses and must pay at least $142 million in damages.
SUBSCRIBERS: Did you receive the new Lawyers USA Weekly Update in your inbox on Monday?
If not, click here to register and learn more now.
